Disease relevance of MAST1

• BACKGROUND: Mast cells are growth factor-rich, bone marrow-derived cells that infiltrate injured tissue where they have been implicated in the pathogenesis of progressive fibrosis [1].
• PURPOSE: Mast cell activation and stress have been suggested as factors in the pathogenesis of interstitial cystitis, a painful disorder of the bladder that is diagnosed more frequently in women and characterized by increased urgency and frequency with absent infection [2].
• Mast Cell Stabilizer Ketotifen [4-(1-Methyl-4-piperidylidene)-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one Fumarate] Prevents Mucosal Mast Cell Hyperplasia and Intestinal Dysmotility in Experimental Trichinella spiralis Inflammation in the Rat [3].
• BACKGROUND: Mast cell-derived vasoactive and pro-inflammatory mediators, particularly histamine, might contribute to local tissue damage and multiorgan dysfunction induced by intestinal ischemia/reperfusion (I/R) [4].
• OBJECTIVE: Mast cell tryptase has been proposed to be involved in the pathogenesis of human inflammatory bowel disease (IBD) [5].

Psychiatry related information on MAST1

• METHODS: Mast cell-deficient (Ws/Ws) rats and wild-type control (+/+) rats were submitted to water avoidance stress or sham stress (1 h/day) for 10 consecutive days, as a model of ongoing life stress [6].

High impact information on MAST1

• Identification of targeting proteinase for rat alpha 1-macroglobulin in vivo. Mast-cell tryptase is a major component of the alpha 1-macroglobulin-proteinase complex endocytosed into rat liver lysosomes [7].
• The putative substrate binding site resembles that of carboxypeptidase A, although other structural features bear more similarity to carboxypeptidase B. Mast cell carboxypeptidase retains enzymatic activity toward a peptide substrate (angiotensin I) while bound within the granular matrix of the rat connective tissue mast cells [8].
• 2. Mast cell degranulation caused by compound 48/80 (10 mg kg-1) or by allergen challenge in rats sensitized to Nippostrongylus brasiliensis also suppressed rat hind paw oedema in the same test [9].
• Three analogs of Mast Cell Degranulating (MCD) peptide with C-terminal and one analog with N- and C-terminal deletions were synthesized and assayed for histamine-releasing activity in mast cells [10].
• 4. Mast cell activation by bradykinin and DSA was not inhibited by anionic polymers, suggesting that both bradykinin and DSA recognize membrane sites as receptors [11].

Anatomical context of MAST1

• 2. Mast cell numbers vary considerably from one individual to another and from one location in the choroid to another [12].
• Inflammatory cells and the epithelium. Mast cell/nerve interactions in the lung in vitro and in vivo [13].
• The non-specific and reversible smooth muscle relaxant activities of the ethanolic extract (EE) of Aristolochia papillaris Mast., a fraction of EE containing tertiary alkaloids (TAF) and of 3 compounds isolated from TAF are reported [14].

Associations of MAST1 with chemical compounds

• 4. Mast cell activation induced by PEI6 was sugar-specifically inhibited by N-acetylglucosamine(Glc-NAc)-specific lectins and/or by sialic acid (Sia)-specific lectins, suggesting that the action sites for PEI6 were glycoproteins having GlcNAc and/or Sia residues [15].

Analytical, diagnostic and therapeutic context of MAST1

• METHODS: Mast cell infiltration and the expression of related chemoattractants was examined following 5/6 nephrectomy, a model of progressive, nonimmune-mediated renal injury [1].
• BACKGROUND AND OBJECTIVE: Mast cell activation by low-level laser therapy (LLLT), leading to degranulation and the release of mediators, may be one of the mechanisms by which LLLT can accelerate tissue repair in mammals [16].

References